newsfilter
← Latest News
GlobeNewswire·

INVO Fertility Announces Third Quarter 2025 Financial Results

  • INVO Fertility, Inc. reported Q3 2025 total revenue of $1,757,094, a 23% increase compared to $1,433,151 in Q3 2024.
  • Consolidated clinic revenue from INVO Centers in Atlanta & Madison increased 21% to $1,722,223.
  • Revenue from all clinics including equity method clinics rose 18% to $1,995,007.
  • The company reported a net loss of $2.6 million for the quarter, compared to a $1.6 million loss in the prior year period.
  • Adjusted EBITDA was $(947,568), slightly worse than $(945,949) in Q3 2024.
  • Organic clinic growth of 23% was driven by increased patient flow at Wisconsin & Georgia locations via telehealth & expanded services.
  • INVOcell device revenue grew 130% year-over-year following improved pricing & expanded training support.
  • A new U.S. policy in October 2025 allows employers to offer standalone infertility benefit packages, potentially expanding IVF access.
  • Management plans to complete at least one acquisition in the coming months from a growing pipeline of interested clinics.
  • Operational efficiencies are being pursued through a strategic partnership with Heidi Health to integrate an AI-powered scribe platform.
  • CEO Steve Shum highlighted progress in organic performance, acquisition opportunities, & device expansion while maintaining a focus on profitability.